Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0224
PERSPECTIVE
|
‘Sequence everything' strategy in the clinical cancer genome era .
|
|
Affiliation: (IG), from the Laboratory of Human Reproductive Genetics, Department of Obstetrics and Gynaecology , Medical School, University of Ioannina, GR 451 10 Ioannina, Greece.
|
Abstract
The free falling costs and the validity of data derived from next-generation sequencing (NGS) technologies have shifted the efforts from research setting to the clinical setting with respect to cancer causal mutations identification and functional genomics. The “sequencing everything” approach by applying NGS with whole-genome sequencing, whole-exome sequencing and transcriptome analysis along with gene expression profiling has recently been reported in two patients with colorectal cancer and melanoma respectively. Whether such a high-throughput technology-based integrative approach cab provide clinically robust information to improve decision making by tailoring a more effective targeted therapy is discussed here.
(Citation: Gastric & Breast Cancer 2011; 11(2): 65-71)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 23 April 2012 |
|
